Qiagen (QGEN) has released an update.
Qiagen reported solid growth in Q3 2024, with net sales reaching $502 million, surpassing expectations. The company increased its full-year adjusted EPS outlook and demonstrated a strong performance in diagnostic solutions, driven by partnerships with pharma giants like AstraZeneca and Eli Lilly. Qiagen’s strategic initiatives have improved profitability and positioned the company for continued growth, with a significant increase in free cash flow.
For further insights into QGEN stock, check out TipRanks’ Stock Analysis page.
